Cyfuse Biomedical K.K. (4892.T)
JPY 970.0
(-2.81%)
JPY 970.0
(-2.81%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.96 Billion JPY | 16.11% |
| 2022 | -3.52 Billion JPY | -91.39% |
| 2021 | -1.84 Billion JPY | -19.48% |
| 2020 | -1.54 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.74 Billion JPY | 7.22% |
| 2024 Q2 | -1.58 Billion JPY | 42.43% |
| 2023 Q3 | -3.02 Billion JPY | 5.64% |
| 2023 FY | -2.96 Billion JPY | 16.11% |
| 2023 Q4 | -2.96 Billion JPY | 2.03% |
| 2023 Q2 | -3.2 Billion JPY | 5.47% |
| 2023 Q1 | -3.38 Billion JPY | 4.03% |
| 2022 FY | -3.52 Billion JPY | -91.39% |
| 2022 Q4 | -3.53 Billion JPY | -131.91% |
| 2022 Q3 | -1.52 Billion JPY | 0.0% |
| 2021 FY | -1.84 Billion JPY | -19.48% |
| 2020 FY | -1.54 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 341.696% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.068% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 100.759% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 99.145% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 16.928% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 92.977% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 95.184% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 96.977% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | -343.894% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 94.287% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 91.006% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 138.947% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 138.051% |
| Tsumura & Co. | 1.61 Billion JPY | 283.33% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 93.295% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 91.402% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 101.714% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 111.121% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 110.216% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 141.937% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 520.564% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 149.412% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 54.569% |
| MedRx Co., Ltd | -1.72 Billion JPY | -72.138% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 66.032% |
| Solasia Pharma K.K. | -668 Million JPY | -343.229% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | -101.285% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 59.179% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 105.238% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 96.992% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 73.397% |